Getting 50% of things right for USD$250 per share still seems like a reasonable target to me
In all seriousness, a bunch of people here know that the "true" value of Bis is far beyond USD$1000 a share - it's a completely unrealisable or unachievable figure. It gets laughed out of the room when brought up. But if a person looks at dosage numbers, share of market and usecases, it's so easy to get to these kinds of figures. We treat a lot of cancers and it looks like we augment and improve other therapies too, PLUS cardio protection. It's very special.
The thing is, business development directors also look at these kinds of calcs - and they target the space between buyout price and total market share/penetration to work out margin.
Bisantrene will be a hot property once it hits the auction block with a full data suite and loads of leads to raise the kinds of insane numbers we're talking about.
USD$250 per share would be a bargain by anyone's metrics.
Getting 50% of things right for USD$250 per share still seems...
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |